HIV Prevention Logo
Meeting category
Date(s)
1 Dec 2021 - 2 Dec 2021
Meeting type
Virtual Meeting
EACCME
4
Organizer

HIV Prevention Summit 2021

Related Enduring Materials

Enduring Materials
Day 1: Prevention Programs of Today / Delivering What We Have
Opening of the Summit -
WHO Perspective on HIV Prevention - What Are the Gaps
Rachel Baggaley, MBBS, MSc
World Health Organization, Switzerland
Session 1: PrEP and PEP -
Session Chairs:
Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Brazil
Nyaradzo Mavis Mgodi, MBChB, MMed
University of Zimbabwe Clinical Trials Research Centre, Zimbabwe
Overview of Clinical Data on the Safety and Efficacy of Antiretroviral Drugs for HIV Prevention
Roy M. Gulick, MD, MPH
Weill Cornell Medicine / New York Presbyterian Hospital, United States
Whatever Happened with PEP?
Fiona Cresswell, PhD, MBChB, BSc, DTM&H, PGCert Epi, DipHIV
MRC/UVRI-LSHTM Uganda Research Unit / Brighton and Sussex Medical School, United Kingdom / Uganda
Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
#1 Corie Cruz Beniasians
United States
Session 2: PrEP Delivery Models -
Session Chairs:
K. Rivet Amico, PhD
University of Michigan, United States
Kenneth H. Mayer, MD
The Fenway Institute, United States
Why Don’t Prescribers Prescribe?
Douglas Krakower, MD
Beth Israel Deaconess Medical Center, The Fenway Institute, Harvard Medical School, United States
Successes to Access PrEP and PEP: End-User Perspective
Gcobisa Madlolo
AfNHi Youth Cohort, South Africa
Successful Models of PrEP Implementation
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
Socio-Demographics of Individuals Initiated on HIV pre-exposure prophylaxis (PrEP) in Nigeria
#2 Augustine Idemudia
Nigeria
Community PrEP Service delivery for Female Sex Workers in Ghana
#3 Guro Lundby Sorensen
Ghana
Poster Viewing Session -
Topics: PrEP and PEP; Vaccine and Monoclonal Antibodies Research; Social Structural Determinants of PEP and PrEP Implementation and Use
Day 2: Prevention Programs of Tomorrow / Developing What We Still Need
Opening of Day 2 -
Opening Words
Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Brazil
Session 3: PrEP and PEP - Future Prospects -
Session Chairs:
Nyaradzo Mavis Mgodi, MBChB, MMed
University of Zimbabwe Clinical Trials Research Centre, Zimbabwe
The Prevention Pipeline and Clinical Trial Design for PrEP
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
Novel Drug Delivery Systems on the Horizon
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Session 4 Abstract-Driven Session -
Session Chairs:
Simon Collins
HIV i-Base, United Kingdom
Donn Colby, MD, MPH
U.S. Military HIV Research Program (MHRP) / Center for Applied Research on Men and Community Health, United States / Vietnam
Uptake of HIV post-exposure prophylaxis, completion rates and selfreported reasons for non-completion among health care workers at Mbarara Regional Referral Hospital
#4 Musiime Muzoora Dan
Uganda
Non-Occupational Post-Exposure Prophylaxis, Post-Violence Care and Ongoing HIV Risk in Kampala Uganda: Missed Opportunities for HIV Prevention through Pre-Exposure Prophylaxis and Other Interventions
#5 & #6 Lisa Mills
Uganda
Intimate partner violence and gender-based violence among people living with HIV in southern Nigeria
#7 Chika Okafor
Nigeria
Session 5: What Is the Future for Vaccines and Monoclonal Antibodies? -
Session Chairs:
Mitchell Warren
AVAC, United States
Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Brazil
Antibody Mediated Prevention of HIV
Myron S. Cohen, MD, BS
University of North Carolina at Chapel Hill, United States
State-of-the-Art and Future Prospects for HIV Vaccines
Glenda E. Gray, MBBCH, FCPaeds (SA), DSc
South African Medical Research Council (SAMRC), South Africa
Overview
Image
HIV Prevention Summit 2021
Welcome

The HIV Prevention Summit 2021 took place as a highly successful summit on 1-2 December 2021. As a registered delegate, you can watch the recordings on the virtual summit portal.

This is the second meeting in the HIV Prevention series. The first meeting in this series was the HIV Prevention Review Meeting 2021. 

This summit aims to increase knowledge among healthcare workers worldwide on the exciting new advancements in HIV prevention that we are currently witnessing.
The program is designed to promote understanding among physicians, nurses, policymakers, and community advocates on antiretroviral drugs for prevention, novel formulations and devices, implementation strategies, individual and community-based behavioural aspects of prevention, as well as insights into the vaccine landscape and prospects of monoclonal antibodies for HIV prevention. The universal educational needs regarding existing and novel prevention approaches will be addressed in the truly global context of the HIV epidemic. 


The registration fees are waived for all healthcare professionals.

Program Director

General Information 

COVID-19 Update
In light of the ongoing COVID-19 situation, the Organizing Committee of the HIV Prevention Summit 2021 has decided to hold this year's program as a virtual meeting in December. The program will be delivered safely and conveniently for all participants and conducted through our interactive online platform.

We are available to answer any questions or concerns that you may have about your participation at the HIV Prevention Summit 2021. For more information, please contact Eva@amededu.com.

To stay updated on developments about this meeting, make sure that you are signed up for our newsletter.
Who Should Attend?
- Physicians involved in HIV care and prevention;
- Pharmacologists, nurses, and other healthcare professionals involved in HIV care and prevention; and
- Healthcare administrators, policymakers, and (non)government representatives.
Learning Objectives
After participating in HIV Prevention Summit 2021, participants will be able to:

- Have an increased knowledge on the epidemiology of HIV and the prevalence of new infections among key populations;
- Understand the clinical data supporting antiretrovirals for the prevention of HIV;
- Describe the pros and cons of different PEP/PrEP formulations;
- Reflect on opportunities and challenges in PEP/PrEP implementation;
- Map key individual and community-based behavioral interventions for HIV prevention; and
- Understand how best to implement peer-supported strategies.
Practical Information 

We trust that the following information (in alphabetical order) will assist you in organizing your participation in HIV Prevention Summit 2021.

Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the program and post-meeting survey.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of meeting, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from the meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending this meeting.
Language
The official language of this meeting is English. Translation will not be provided.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Payment and Procedure of Online Registration
The registration fee will be waived for healthcare professionals.
You will get a confirmation of your registration within 1-5 business days. If you do not receive a confirmation, please contact Eva@amededu.com.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the meeting is finished, provided that speakers have given permission to do so.
Committees
Program Director
Organizing Committee
Donn Colby 2020
Donn Colby, MD, MPH
U.S. Military HIV Research Program (MHRP) / Center for Applied Research on Men and Community Health, United States / Vietnam

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Support
Acknowledgment
This educational activity is partially supported by an independent educational grant from MSD. MSD is not involved in the development of content or the selection of faculty for this educational activity.
Endorsers
Accreditation
Accreditation Statement

The HIV Prevention Summit 2021, Utrecht, Netherlands, 01/12/2021-02/12/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form.

Media
Invitations to join the HIV Prevention Summit 2021

See the invitations from our faculty members to join the HIV Prevention Summit 2021 below.

Fiona Cresswell, PhD, MBChB, BSc, DTM&H, PGCert Epi, DipGUM, DFSRH
Brighton and Sussex Medical School, United Kingdom
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Glenda E. Gray, MBBCH, FCPaeds (SA), DSc
South African Medical Research Council (SAMRC), South Africa
Language